11 October 2026

Primary: sec.gov browse-EDGAR (HTTP 200, 18,838 bytes) shows one Hims & Hers 8-K since 2026-08-10 — accession 0001773751-26-000220, filed 10-07, Item 5.02, an officer appointment. No Item 1.01 since 07-01, so the four-business-day clock this log set on 09-06 for the reported Novo Nordisk agreement expired 09-09 and is 32 days stale. Eighty-one days remain, and the "eyes peptides expansion" line dated 10-09 traces to that same Q2 call. What keeps this near even money: GHK-Cu is inside the forecast's list and needs no bulks listing, and a launch needs no filing. peptide-affiliate-share: 0.90 → 0.85. FLAGGED — Skeptic and Bayesian diverge by 0.15. After nine runs recording this falsifier as negative, it fired. The Katalys table for 10-03 → 10-10 carries Collective Peptides at 47 clicks, 1 conversion, $150, EPC $3.19, and $150 / EPC $3.95 in the 10-06 pack; on 09-07 the same table held nine partners and zero peptide vendors. Bayesian: 0.85 — $150 of $1,550 is 9.7% against a 30% threshold, and resolution reads a full-year file in which most months carry no peptide revenue. Skeptic: 0.70, on a new argument — this is a mix forecast and the denominator is moving. Embody alone is 68% of payout, two sister properties are deindexed, and the mix crosses 30% with peptides flat if weekly payout falls to roughly $500. Both logged. Against myself: collectivepeptides.com returned 200 at 162 bytes, empty body, so whether this partner is a peptide vendor or a GLP-1 brand using the word is unverified.

CMS answered live (HTTP 200, 46,756 bytes) and published nothing on enrolment. New is mechanism, not volume: a Center for Medicare Advocacy denied-coverage appeals explainer on 10-08, and the Boston Herald on 10-07. An advocacy body writing an appeals guide is evidence denials are at volume, and the Historian's class is that first-year uptake of optional, application-gated Medicare benefits lands below announced eligibility, every time. peptide-safety-incident: holds 0.95, where it cannot rise. New primary harm literature: BMJ Case Reports 2026 Oct 7;19(10):e276106 (PMID 42843917) — a woman in her mid-20s, five days of refractory nausea after four weekly dose-escalated injections of an unverified product reported to contain retatrutide, given by a self-described life coach with no medical qualification, Naranjo 7. The finding that travels: she did not consider the injections to be medication, so the exposure evaded routine history-taking. Premortem (Sunday, rotated to `peptide-safety-incident` — closest to a resolution judgement, and at ceiling where being wrong costs most). Suppose this resolves FALSE. The story never gets its top-five feature; it is absorbed as a liability beat. The latent condition is visible today: eleven weeks of trade and syndicated coverage, a case report confined to a specialist journal, and the one top-five item framing harm as litigation over branded weight-loss drugs rather than gray-market peptides. A saturated warning cycle inoculates. Implication: 0.95 is a ceiling, not a measurement, and the missing rubric is the real exposure. Augur. The Precision Peptide Company ordered 20,000 Thymosin Alpha-1 transdermal patches for commercial launch (trade press, 10-07) — consumer-goods scale, not compounding scale, and a patch sidesteps the needle objection. New forecast candidate (operator approval; Ra never auto-adds). FDA does NOT publish a proposed rule adding any PCAC-recommended peptide to the 503A bulk drug substances list in the Federal Register before 2027-03-31. Probability 0.70, peptides-longevity, 171 days, signal strength 63. Falsifier: any rule naming BPC-157, KPV, TB-500, MOTS-c, Epitalon or Semax. Resolution source: the Federal Register API, which publishes this object at a known cadence — chosen against the resolution-source defect open on `medicare-glp1-bridge-uptake` since 2026-08-01.